{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"45.9","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"45.9","value":"0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"36.9","value":"0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"45.9","value":"0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"9.7","value":"1.82"},{"groupId":"OG005","lowerLimit":"0.0","upperLimit":"45.9","value":"0"},{"groupId":"OG006","lowerLimit":"0.0","upperLimit":"7.1","value":"0"},{"groupId":"OG007","lowerLimit":"0.0","upperLimit":"7.1","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"55"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"}],"units":"Participants"}],"description":"ORR is defined as the proportion of participants who achieve a CR or PR per RECIST v1.1. ORR and the corresponding 95% two-sided confidence interval were derived.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received intermittent dose of RMC-4630 80 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20 mg QD 21days on and 7 days off of a 28-day cycle.","id":"OG000","title":"Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)"},{"description":"Participants who received intermittent dose of RMC-4630 80mg on D1 and D4 of a 28-day cycle and Cobimetinib 40mg QD 21days on and 7 days off of a 28-day cycle.","id":"OG001","title":"Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D4 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.","id":"OG002","title":"Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 20mg QD 21days on and 7 days off of a 28-day cycle.","id":"OG003","title":"Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 40mg D1 and D2 of a 28-day cycle.","id":"OG004","title":"Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and Cobimetinib 60mg D1 and D2 of a 28-day cycle.","id":"OG005","title":"Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2"},{"description":"Participants who received intermittent dose of RMC-4630 100 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.","id":"OG006","title":"Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)"},{"description":"Participants who received intermittent dose of RMC-4630 140 mg on D1 and D2 of a 28-day cycle and daily dose of Osimertinib 80 mg from D1 through D28 of a 28-day cycle.","id":"OG007","title":"Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Response assessment occurs from the start of intervention until the date of documented disease progression per RECIST 1.1 or the date of subsequent therapy, whichever occurs first.","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"% of participants"}